Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aroplatin + capecitabine
- Development stage
- Preclinical
- Lead developer
- Agenus
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Aroplatin + capecitabine is a combination of two chemotherapeutic agents used in cancer treatment. Aroplatin (L-NDDP) is a lipophilic platinum analog designed to overcome resistance to traditional platinum-based drugs and enhance delivery into tumor cells. Capecitabine is an orally administered prodrug that is converted in vivo to 5-fluorouracil (5-FU), which acts as an antimetabolite by interfering with DNA synthesis and function[1][4][5]. Capecitabine selectively targets tumor tissues due to higher concentrations of activating enzymes in tumors. The combination aims to exploit the complementary mechanisms of action—DNA crosslinking by the platinum agent and inhibition of DNA synthesis by 5-FU—to maximize anti-tumor efficacy. Capecitabine has been approved for use in various cancers including colorectal, breast, gastric, esophageal, gastroesophageal junction adenocarcinoma, and pancreatic cancer[2][4][5]. Aroplatin has primarily been investigated in clinical trials for solid tumors.
- Brand names
- Xeloda
- Other names
- aroplatinL-NDDPcapecitabine
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Aroplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aroplatin + capecitabine.